Investing
Radiopharm Theranostics (RAD:AU) has announced Acceleration of RAD204 Phase 1 dose escalation trial Download the PDF here. This post appeared first on investingnews.com
Connect with us
Hi, what are you looking for?
Joyful Retirement Secrets
- Politics
American creating deepfakes targeting Harris works with Russian intel, documents show
Early voting in Wisconsin slowed by label printing problems
Trump’s exaggerated claim that Pennsylvania has 500,000 fracking jobs
Tucker Carlson says father Trump will give ‘spanking’ at rowdy Georgia rally
A GOP operative accused a monastery of voter fraud. Nuns fought back.
- Investing
Rick Rule, Ed Steer, Vince Lanci and More — Our Top 5 Interviews of the Year
Jeffrey Christian: Gold, Silver at Record Prices, Expect Spikes Higher in 2026
Biotech Market Forecast: Top Trends for Biotech in 2026
Altius Minerals to Expand Portfolio with C$520 Million Lithium Royalty Deal
Craig Hemke: Silver, Gold’s “Outstanding” Year — Will 2026 Bring a Repeat?
- Tech News
There’s already a risk COP29 will end in failure – and damage of Trump 2.0 could yet spread
Battle lines drawn on new climate fund despite ‘shot in the arm’ cash injection at COP29
The Guardian quits Elon Musk’s X social media platform
Argentina walks away from COP29 – amid fears Trump may pull US out of Paris climate deal
Apple sued by Which? over iCloud use – with potential payout for 40 million UK customers
- Stock
Chart Mania – 23 ATR Move in QQQ – Metals Lead 2025 – XLV Oversold – XLU Breakout – ITB Moment of Truth
S&P 500 Breaking Out Again: What This Means for Your Portfolio
Momentum Leaders Are Rotating — Here’s How to Find Them
Is META Breaking Out or Breaking Down?
A Wild Ride For the History Books: 2025 Mid-Year Recap
Investing
Don Durrett: Gold, Silver Price Targets and 15 ‘Must-Own’ Silver Stocks Kicking off the list in the fifth spot is Don Durrett of GoldStockData.com....
Investing
Jeffrey Christian, managing partner at CPM Group, shares his outlook for gold and silver in 2026, explaining why he expects higher prices for the...
Investing
The biotech sector is entering 2026 with a positive outlook, characterized by reasonable valuations, robust oncology momentum and supportive policy tailwinds. This combination is...